Get started

Financials · RKDA

Arcadia Biosciences Inc. (RKDA) financials

For the twelve months ended Jun 30, 2026, Arcadia Biosciences Inc. reported $4.75M of revenue and -$11.13M of net income.

Revenue, TTM
$4.75M
Revenue growth, YoY
-12.2%
Net income, TTM
-$11.13M
Net margin
-234.5%
EPS, diluted, TTM
-$4.55
Cash
$4.18M
P/S
0.09
Market cap
$412,126
Annual revenue$4.86M
FY2016FY2025
Annual net income-$2.34M
FY2016FY2025
Annual free cash flow-$4.74M
FY2016FY2025

RKDA revenue and earnings growth

RKDA revenueQ2 2026$1.44M

Quarter YoY
-0.8%
QoQ
+31.2%
FY YoY
-3.7%
5Y CAGR
-9.6%
10Y CAGR
-1.1%

RKDA revenue was $1.44M in fiscal Q2 2026 (ended Jun 30, 2026), down 0.8% from a year earlier and up 31.2% from the prior quarter. For the full fiscal 2025 it was $4.86M, down 3.7% from fiscal 2024. Compound annual growth was -9.6% over 5 years and -1.1% over 10 years. It rose in 4 of the last 10 fiscal years.

RKDA net incomeQ2 2026-$6.27M

RKDA net income was -$6.27M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.46M a year earlier. For the full fiscal 2025 it was -$2.34M, compared with -$7.04M in fiscal 2024.

RKDA EPSQ2 2026-$2.09

RKDA diluted EPS was -$2.09 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.71, compared with -$5.17 in fiscal 2024.

RKDA free cash flowQ4 2025-$861.0K

RKDA free cash flow was -$861.0K in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$2.21M a year earlier. For the full fiscal 2025 it was -$4.74M, compared with -$9.64M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$4.86M$5.04M$4.45M$7.42M$6.78M$8.03M$1.17M$1.46M$4.03M$3.19M
Cost of revenue$3.10M$2.96M$2.17M$6.10M$8.71M$5.20M--$283.0K$895.0K
Gross profit$1.76M$2.08M$2.28M$1.32M-$1.93M$2.83M--$3.74M$2.29M
Research and development$9.0K$53.0K$64.0K$1.51M$3.89M$7.96M$7.10M$6.07M$7.41M$8.66M
Selling, general and admin$7.00M$9.64M$8.23M$15.04M$22.94M$16.47M$13.57M$11.60M$10.65M$12.25M
Operating income-$2.50M-$3.65M-$6.10M-$14.01M-$35.53M-$12.78M-$19.38M-$16.87M-$14.31M-$18.62M
Interest expense----$20.0K$47.0K$5.0K-$747.0K$1.32M
Pre-tax income-$2.33M-$4.31M-$5.32M-$10.81M-$16.13M-$6.15M-$28.87M-$13.47M-$15.68M-$19.60M
Income tax$8.0K$8.0K$8.0K$14.0K$2.0K-$124.0K$2.0K$10.0K$26.0K$25.0K
Net income-$2.34M-$7.04M-$13.98M-$15.38M-$14.66M-$4.66M-$28.80M-$13.48M-$15.71M-$19.62M
EPS, basic-$1.71-$5.17-$11.29-$17.67-$1102.40-$18.80-$181.20-$143.20-$291.20-$354.00
EPS, diluted-$1.71-$5.17-$11.29-$17.67-$1102.40-$18.80-$181.20-$143.20-$291.20-$354.00
Diluted shares1.4M1.4M1.2M599,38913,300.4248,975.45159,077.894,160.47553,905.02555,458.525

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$259.0K$4.24M$6.52M$20.64M$28.68M$14.04M$8.42M$12.00M$9.13M$2.01M
Short-term investments$4.30M$0$5.12M$0-$11.63M$16.91M$9.82M$3.90M$48.55M
Receivables----$1.37M$1.41M$602.0K$165.0K$1.23M$349.0K
Inventory$1.21M$904.0K$837.0K$2.32M$4.43M$3.81M$1.79M$181.0K$229.0K$252.0K
Current assets$6.36M$9.24M$14.97M$25.40M$35.39M$31.70M$28.44M$22.88M$15.05M$52.22M
Goodwill-----$408.0K----
Total assets$6.55M$13.52M$19.70M$28.92M$43.92M$47.35M$32.57M$24.02M$16.57M$56.57M
Current liabilities$2.06M$2.56M$3.59M$4.21M$5.04M$6.31M$5.71M$3.05M$3.52M$3.13M
Short-term debt----$0$1.14M$24.0K--$0
Long-term debt----$0$2.10M$107.0K--$25.13M
Total debt----$0$3.25M$131.0K$0$0$25.13M
Total liabilities$2.41M$7.29M$7.00M$8.02M$12.72M$18.80M$24.25M$11.21M$8.56M$34.38M
Shareholders' equity$4.14M$6.22M$12.70M$20.90M$31.20M$28.55M$8.32M$12.81M$8.01M$22.20M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$4.74M-$9.63M-$15.29M-$13.98M-$25.87M-$30.22M-$17.20M-$13.63M-$13.96M-$17.05M
Capital expenditures$0$16.0K$5.0K$72.0K$1.01M$2.33M$1.48M$250.0K$79.0K$231.0K
Free cash flow-$4.74M-$9.64M-$15.30M-$14.05M-$26.88M-$32.55M-$18.68M-$13.88M-$14.04M-$17.29M
Investing cash flow$750.0K$7.34M-$4.34M$1.42M$16.61M$17.28M-$8.37M-$5.97M$47.18M-$5.30M
Financing cash flow$6.0K$9.0K$5.51M$4.52M$21.90M$20.56M$21.99M$22.48M-$26.10M$396.0K
Stock-based compensation$234.0K$512.0K$717.0K$1.11M$1.54M$2.04M$2.29M$1.55M$1.47M$1.06M
Depreciation and amortization-------$154.0K$279.0K$304.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-3.7%13.3%-40.0%9.4%-15.6%587.3%-20.2%-63.6%26.3%-41.1%
Gross margin36.2%41.3%51.2%17.8%-28.4%35.3%--93.0%71.9%
Operating margin-51.5%-72.3%-137.0%-188.8%-524.0%-159.0%-1657.9%-1152.3%-355.6%-584.1%
Net margin-48.1%-139.5%-313.9%-207.3%-216.2%-57.9%-2464.1%-920.8%-390.1%-615.6%
Free cash flow margin-97.6%-191.1%-343.5%-189.4%-396.4%-405.2%-1597.5%-948.2%-348.8%-542.2%
Return on equity-56.5%-113.1%-110.1%-73.6%-47.0%-16.3%-346.0%-105.2%-196.2%-88.4%
Return on assets-35.7%-52.1%-71.0%-53.2%-33.4%-9.8%-88.4%-56.1%-94.8%-34.7%
Current ratio3.093.614.176.037.025.024.987.494.2716.69
Debt to equity----0.000.110.020.000.001.13

Source: XBRL data Arcadia Biosciences Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Mar 20, 2018; 1-for-40, first reported May 15, 2023.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

RKDA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
RKDA$4.75M-12.2%-$11.13M-234.5%$412,126
SHEL$273.73B-5.3%$17.84B6.5%$273.51B
TTE$201.20B-6.2%$13.13B6.5%$192.00B
PBR$89.19B-2.4%$19.63B22.0%$118.25B
CNQC$38.76B+8.7%C$10.82B27.9%$98.26B
E€82.15B-7.5%€2.61B3.2%$87.98B
EOG$29.73B+31.7%$8.19B27.5%$76.96B
OXY$25.75B+36.9%$7.50B29.1%$55.74B
OKE$43.19B+36.8%$4.07B9.4%$54.21B

RKDA FAQ

8 questions
  • What is RKDA revenue?
    Arcadia Biosciences Inc. (RKDA) reported $4.75M of revenue for the twelve months ended Jun 30, 2026. That is down 12.2% from the year before. Revenue for fiscal 2025 was $4.86M.
  • Is RKDA profitable?
    No. Arcadia Biosciences Inc. reported a net loss of $11.13M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does RKDA have?
    Arcadia Biosciences Inc. reported $4.18M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is RKDA revenue growing?
    Arcadia Biosciences Inc.'s revenue changed -3.7% in fiscal 2025, to $4.86M. Its compound annual growth rate was -9.6% over 5 years and -1.1% over 10 years.
  • What is RKDA gross margin?
    Arcadia Biosciences Inc.'s gross profit was $1.64M on $4.75M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 34.6%.
  • What is RKDA earnings per share?
    Diluted earnings per share were -$4.55 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did RKDA last report financial results?
    The latest statements here come from Arcadia Biosciences Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this RKDA financial data come from?
    Quantisnow builds these statements from the structured XBRL data Arcadia Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.